ClinicalTrials.gg
Active, not recruitingNCT07212426Updated Jan 16, 2026

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.

A Phase 2 interventional study of LP-005 Injection in PNH - Paroxysmal Nocturnal Hemoglobinuria, sponsored by Longbio Pharma. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.
  • Registered 10 months after the study started (first participant enrolled Nov 2024, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
30th of 47
30 · median 40
Started
2024
with 11 others
Phase 2
13 of 51
4 open now
Primary completion
2026-05
later than 9 of 28 live
Registered
41st of 51
by date
Lead sponsor
3 of 51
Longbio Pharma

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 30th largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 9 of the 28 other live ones, and was the 41st registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

03

Conditions studied

  • PNH - Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 to 65 years.
  • Diagnosis of PNH based on flow cytometry with clone size > 10% by granulocytes.
  • Presence of one or more PNH-related signs or symptoms within 3 months prior to screening or a history of transfusion due to PNH.
  • LDH level ≥2.0×(ULN).
  • level \<100 g/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Active or suspected active viral, bacterial, fungal, or parasitic infection within 14 days prior to screening.
  • History of meningococcal infection.
  • History of splenectomy or congenital asplenia.
  • History of systemic disease or known/suspected immunodeficiency.
  • History of hematopoietic stem cell transplantation.
  • Use of any complement inhibitor within 3 months prior to screening or within 5 drug half-lives (whichever is longer).
  • Pregnant or breastfeeding women, or women planning to become pregnant during the study or follow-up period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    LP-005 900 mg

    Patients will receive intravenous infusion of LP-005 Injection at a dose of 900 mg once every 4 weeks.

    Biological: LP-005 Injection

  • Experimental
    LP-005 1200 mg

    Patients will receive intravenous infusion of LP-005 Injection at a dose of 1200 mg once every 4 weeks.

    Biological: LP-005 Injection

  • Experimental
    LP-005 1500 mg

    Patients will receive intravenous infusion of LP-005 Injection at a dose of 1500 mg once every 4 weeks.

    Biological: LP-005 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in serum lactate dehydrogenase (LDH) levels.

    Time frame: Baseline and at Week 12.

  2. Proportion of participants with ≥2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion.

    Time frame: Baseline and at Week 24.

Secondary outcomes

  1. Proportion of participants with ≥2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion.

    Time frame: Baseline and at Week 12 and 48

  2. Proportion of participants who are transfusion-free.

    Time frame: Baseline to Week 12, 24 and 48

  3. Change from Baseline in the number of red blood cell (RBC) transfusions.

    Time frame: Baseline to Week 24 and 48.

  4. Change from Baseline in hemoglobin levels.

    Time frame: Baseline, Week 12, 24 and 48

  5. Proportion of participants achieving hemoglobin levels ≥100 g/L in the absence of transfusion.

    Time frame: Baseline, Week 12, 24 and 48

  6. Proportion of participants with LDH levels normalized.

    Time frame: Baseline, Week 12, 24 and 48

  7. Changes in serum complement hemolytic activity.

    Time frame: Observation from Predose on Day 1 through 337 days post-administration.

  8. Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

    FACIT-F is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. The higher the score, the better the QOL.

    Time frame: Baseline and at Week 12, 36, and 48.

  9. Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

    Time frame: Baseline up to approximately 13 months.

  10. Serum concentrations of LP-005.

    Time frame: Observation from Predose on Day 1 through 337 days post-administration.

  11. Number of Participants with Treatment-emergent Anti-Drug Antibodies (ADA) and neutralizing antibodies (Nab) Response to LP-005.

    Time frame: Observation from Predose on Day 1 through 337 days post-administration.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2026, 17 months after the start.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 17 months is close to that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 8, 2025
StartActual
Nov 14, 2024
Primary completionEst.
May 6, 2026
CompletionEst.
Mar 31, 2028
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07212426
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Nov 14, 2024
Primary completion
May 6, 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jan 16, 2026

Study contacts

Guangsheng He
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-005

Start the discussion